Scott Stephen - Feb 17, 2023 Form 4 Insider Report for cbdMD, Inc. (YCBD)

Role
Director
Signature
/s/ Scott Stephen
Stock symbol
YCBD
Transactions as of
Feb 17, 2023
Transactions value $
$0
Form type
4
Date filed
2/22/2023, 03:29 PM
Previous filing
Apr 19, 2022
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YCBD Common Stock Award $0 +5K +9.79% $0.00 56.1K Feb 17, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YCBD Stock Options (Right to Buy) Award +30K 30K Feb 17, 2023 Common Stock 30K $0.28 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted shares of common stock were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning February 16, 2023. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The restricted shares of common stock vest quarterly in equal increments on June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, subject to continued service as a director of the Issuer on each applicable vesting date.
F2 The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning February 16, 2023. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The stock options are fully vested.
F3 Not applicable.